The FDA accepts supplemental new drug application for selinexor as a treatment for R/R DLBCL

On February 19, 2020, the U.S. Food and Drug Administration (FDA) accepted a supplemental new drug application (sNDA) filing for selinexor for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, who have received  ≥ 2 prior therapies. Selinexor is a first-in-class, oral selective inhibitor of nuclear export (SINE) compound that selectively binds and inhibits the nuclear export protein exportin 1 (XPO1).¹

Selinexor has previously received both orphan drug and fast track designations from the FDA for the treatment of patients with relapsed or refractory DLBCL.² This was based on the results from the SADAL study (NCT02227251), click here to watch John Kuruvilla discuss it.

Selinexor is approved for the treatment of relapsed and refractory multiple myeloma, and there are ongoing trials for liposarcoma and endometrial cancer.